- Home
- LANV vs CRVO Comparison
LANV vs CRVO Comparison
Compare LANV & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- CRVO
- Stock Information
- Founded
- LANV 2015
- CRVO 2001
- Country
- LANV China
- CRVO United States
- Employees
- LANV N/A
- CRVO N/A
- Industry
- LANV Blank Checks
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- LANV Finance
- CRVO Health Care
- Exchange
- LANV Nasdaq
- CRVO Nasdaq
- Market Cap
- LANV 275.9M
- CRVO 67.4M
- IPO Year
- LANV N/A
- CRVO N/A
- Fundamental
- Price
- LANV $2.50
- CRVO $7.16
- Analyst Decision
- LANV
- CRVO Strong Buy
- Analyst Count
- LANV 0
- CRVO 7
- Target Price
- LANV N/A
- CRVO $19.33
- AVG Volume (30 Days)
- LANV 37.9K
- CRVO 161.2K
- Earning Date
- LANV 08-25-2025
- CRVO 08-08-2025
- Dividend Yield
- LANV N/A
- CRVO N/A
- EPS Growth
- LANV N/A
- CRVO N/A
- EPS
- LANV N/A
- CRVO N/A
- Revenue
- LANV $340,211,202.00
- CRVO $9,308,215.00
- Revenue This Year
- LANV $11.74
- CRVO N/A
- Revenue Next Year
- LANV $11.11
- CRVO N/A
- P/E Ratio
- LANV N/A
- CRVO N/A
- Revenue Growth
- LANV N/A
- CRVO 15.14
- 52 Week Low
- LANV $0.91
- CRVO $1.80
- 52 Week High
- LANV $2.69
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- LANV 67.85
- CRVO 51.63
- Support Level
- LANV $2.22
- CRVO $5.45
- Resistance Level
- LANV $2.47
- CRVO $7.55
- Average True Range (ATR)
- LANV 0.20
- CRVO 0.59
- MACD
- LANV 0.04
- CRVO 0.14
- Stochastic Oscillator
- LANV 97.03
- CRVO 75.71
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.